USA - NASDAQ:SSKN - US86272A3059 - Common Stock
The current stock price of SSKN is 1.6 USD. In the past month the price decreased by -6.36%. In the past year, price decreased by -47.6%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.05 | 217.56B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.72 | 196.67B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.59 | 146.83B | ||
| SYK | STRYKER CORP | 26.95 | 135.72B | ||
| IDXX | IDEXX LABORATORIES INC | 55.85 | 56.34B | ||
| BDX | BECTON DICKINSON AND CO | 12.21 | 50.48B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.18 | 48.55B | ||
| RMD | RESMED INC | 25.13 | 36.31B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.96 | 33.45B | ||
| PODD | INSULET CORP | 76.72 | 22.84B | ||
| DXCM | DEXCOM INC | 30.13 | 21.98B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.86 | 17.40B |
STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. The company is headquartered in Horsham, Pennsylvania and currently employs 106 full-time employees. The company went IPO on 2005-10-28. The firm is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
STRATA SKIN SCIENCES INC
5 Walnut Grove Drive, Suite 140
Horsham PENNSYLVANIA 19044 US
CEO: Robert J. Moccia
Employees: 106
Phone: 12156193200
STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. The company is headquartered in Horsham, Pennsylvania and currently employs 106 full-time employees. The company went IPO on 2005-10-28. The firm is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.
The current stock price of SSKN is 1.6 USD. The price decreased by -1.23% in the last trading session.
SSKN does not pay a dividend.
SSKN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
STRATA SKIN SCIENCES INC (SSKN) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
STRATA SKIN SCIENCES INC (SSKN) currently has 106 employees.
You can find the ownership structure of STRATA SKIN SCIENCES INC (SSKN) on the Ownership tab.
ChartMill assigns a fundamental rating of 1 / 10 to SSKN. Both the profitability and financial health of SSKN have multiple concerns.
Over the last trailing twelve months SSKN reported a non-GAAP Earnings per Share(EPS) of -2.84. The EPS decreased by -16.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.56% | ||
| ROE | -3746.75% | ||
| Debt/Equity | 49.58 |
8 analysts have analysed SSKN and the average price target is 8.16 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.6.
For the next year, analysts expect an EPS growth of 37.76% and a revenue growth -1.34% for SSKN